Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism

[1]  R. Bergman,et al.  FGF19 action in the brain induces insulin-independent glucose lowering. , 2013, The Journal of clinical investigation.

[2]  S. Chua,et al.  Identification of a Loss-of-Function Mutation in Ube2l6 Associated With Obesity Resistance , 2013, Diabetes.

[3]  J. P. Warne,et al.  Metabolic transceivers: in tune with the central melanocortin system , 2013, Trends in Endocrinology & Metabolism.

[4]  B. Angelin,et al.  Circulating fibroblast growth factors as metabolic regulators--a critical appraisal. , 2012, Cell metabolism.

[5]  Dong-Hyun Kim,et al.  Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho , 2012, Proceedings of the National Academy of Sciences.

[6]  J. H. Bekker,et al.  The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. , 2012, Endocrinology.

[7]  B. Lemon,et al.  Characterization of a FGF19 Variant with Altered Receptor Specificity Revealed a Central Role for FGFR1c in the Regulation of Glucose Metabolism , 2012, PloS one.

[8]  Xiaokun Li,et al.  Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB , 2012, PloS one.

[9]  R. Palmiter,et al.  Ablation of neurons expressing agouti-related protein, but not melanin concentrating hormone, in leptin-deficient mice restores metabolic functions and fertility , 2012, Proceedings of the National Academy of Sciences.

[10]  Jun Li,et al.  Amelioration of Type 2 Diabetes by Antibody-Mediated Activation of Fibroblast Growth Factor Receptor 1 , 2011, Science Translational Medicine.

[11]  S. Kliewer,et al.  FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. , 2011, Cell metabolism.

[12]  M. Schwartz,et al.  Leptin and the central nervous system control of glucose metabolism. , 2011, Physiological reviews.

[13]  S. Kliewer,et al.  FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis , 2011, Science.

[14]  A. Peterson,et al.  FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways , 2011, PloS one.

[15]  P. Ciofi.  The arcuate nucleus as a circumventricular organ in the mouse , 2011, Neuroscience Letters.

[16]  S. Bloom,et al.  Remission of Type 2 Diabetes After Gastric Bypass and Banding: Mechanisms and 2 Year Outcomes , 2010, Annals of surgery.

[17]  S. L. Dun,et al.  Neuronostatin is co-expressed with somatostatin and mobilizes calcium in cultured rat hypothalamic neurons , 2010, Neuroscience.

[18]  A. Nederveen,et al.  The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[19]  N. Stanietsky,et al.  The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity , 2009, Proceedings of the National Academy of Sciences.

[20]  J. Chiang,et al.  Bile acids: regulation of synthesis , 2009, Journal of Lipid Research.

[21]  L. Olofsson,et al.  Functional requirement of AgRP and NPY neurons in ovarian cycle-dependent regulation of food intake , 2009, Proceedings of the National Academy of Sciences.

[22]  B. Lemon,et al.  Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice , 2009, Proceedings of the National Academy of Sciences.

[23]  M. Mohammadi,et al.  The FGF family: biology, pathophysiology and therapy , 2009, Nature Reviews Drug Discovery.

[24]  S. Strom,et al.  Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α‐hydroxylase gene expression , 2009, Hepatology.

[25]  J. D. Dunbar,et al.  FGF‐21/FGF‐21 receptor interaction and activation is determined by βKlotho , 2008, Journal of cellular physiology.

[26]  D. Stejskal,et al.  Fibroblast growth factor‐19: Development, analytical characterization and clinical evaluation of a new ELISA test , 2008, Scandinavian journal of clinical and laboratory investigation.

[27]  S. Kliewer,et al.  Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21* , 2007, Journal of Biological Chemistry.

[28]  Peter Bohlen,et al.  Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. , 2007, American journal of physiology. Endocrinology and metabolism.

[29]  H. Münzberg,et al.  Appropriate Inhibition of Orexigenic Hypothalamic Arcuate Nucleus Neurons Independently of Leptin Receptor/STAT3 Signaling , 2007, The Journal of Neuroscience.

[30]  M. W. Schwartz,et al.  Central nervous system control of food intake and body weight , 2006, Nature.

[31]  Sanda Šulić,et al.  Inactivation of S6 ribosomal protein gene in T lymphocytes activates a p53-dependent checkpoint response. , 2005, Genes & development.

[32]  R. Soriano,et al.  Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. , 2004, Endocrinology.

[33]  S. Kliewer,et al.  Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. , 2003, Genes & development.

[34]  T. Alexandrides,et al.  Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. , 2003, Diabetes.

[35]  M. Hagan.  Peptide YY: a key mediator of orexigenic behavior , 2002, Peptides.

[36]  L. Rossetti,et al.  Central melanocortin receptors regulate insulin action. , 2001, The Journal of clinical investigation.

[37]  C. Deng,et al.  Elevated Cholesterol Metabolism and Bile Acid Synthesis in Mice Lacking Membrane Tyrosine Kinase Receptor FGFR4* , 2000, The Journal of Biological Chemistry.

[38]  Santanu Banerjee.  Original article , 1998, Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India.

[39]  J. Geisler,et al.  Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Richard P. Woychik,et al.  Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor , 1994, Nature.

[41]  J. Verbalis,et al.  c-Fos and Related Immediate Early Gene Products as Markers of Activity in Neuroendocrine Systems , 1993, Frontiers in Neuroendocrinology.

[42]  S. Woods,et al.  Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. , 2013, Endocrinology.

[43]  R. Muniyappa,et al.  Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. , 2008, American journal of physiology. Endocrinology and metabolism.

[44]  D. French,et al.  Printed in U.S.A. Copyright © 2002 by The Endocrine Society Transgenic Mice Expressing Human Fibroblast Growth Factor-19 Display Increased Metabolic Rate and Decreased Adiposity , 2022 .

[45]  G. Hooiveld,et al.  Bmc Medical Genomics the Role of the Small Intestine in the Development of Dietary Fat-induced Obesity and Insulin Resistance in C57bl/6j Mice , 2022 .